Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.97EUR
−435.96 MEUR
32.87 MEUR
94.66 M
About Intellia Therapeutics, Inc.
Sector
Industry
CEO
John M. Leonard
Website
Headquarters
Cambridge
Employees (FY)
526
Founded
2014
FIGI
BBG00CW7Q771
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where 38I is featured.
Frequently Asked Questions
The current price of 38I is 23.24 EUR — it has decreased by 1.27% in the past 24 hours. Watch INTELLIA THERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange INTELLIA THERAPEUTICS INC stocks are traded under the ticker 38I.
38I stock has risen by 9.99% compared to the previous week, the month change is a 3.81% fall, over the last year INTELLIA THERAPEUTICS INC has showed a 43.93% decrease.
We've gathered analysts' opinions on INTELLIA THERAPEUTICS INC future price: according to them, 38I price has a max estimate of 134.55 EUR and a min estimate of 22.42 EUR. Watch 38I chart and read a more detailed INTELLIA THERAPEUTICS INC stock forecast: see what analysts think of INTELLIA THERAPEUTICS INC and suggest that you do with its stocks.
38I stock is 2.24% volatile and has beta coefficient of 3.06. Track INTELLIA THERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is INTELLIA THERAPEUTICS INC there?
Today INTELLIA THERAPEUTICS INC has the market capitalization of 2.27 B, it has increased by 14.87% over the last week.
Yes, you can track INTELLIA THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
INTELLIA THERAPEUTICS INC is going to release the next earnings report on Aug 1, 2024. Keep track of upcoming events with our Earnings Calendar.
38I earnings for the last quarter are −1.04 EUR per share, whereas the estimation was −1.27 EUR resulting in a 18.02% surprise. The estimated earnings for the next quarter are −1.14 EUR per share. See more details about INTELLIA THERAPEUTICS INC earnings.
INTELLIA THERAPEUTICS INC revenue for the last quarter amounts to 26.82 M EUR, despite the estimated figure of 10.42 M EUR. In the next quarter, revenue is expected to reach 18.38 M EUR.
38I net income for the last quarter is −99.57 M EUR, while the quarter before that showed −119.74 M EUR of net income which accounts for 16.84% change. Track more INTELLIA THERAPEUTICS INC financial stats to get the full picture.
No, 38I doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 17, 2024, the company has 526.00 employees. See our rating of the largest employees — is INTELLIA THERAPEUTICS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. INTELLIA THERAPEUTICS INC EBITDA is −470.71 M EUR, and current EBITDA margin is −1.40 K%. See more stats in INTELLIA THERAPEUTICS INC financial statements.
Like other stocks, 38I shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INTELLIA THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So INTELLIA THERAPEUTICS INC technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating INTELLIA THERAPEUTICS INC stock shows the sell signal. See more of INTELLIA THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.